Damora Therapeutics, Inc. (DMRA) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $257.62M | +1717.5% |
| 2024 | $14.18M | -34.0% |
| 2023 | $21.46M | -34.5% |
| 2022 | $32.79M | -47.6% |
| 2021 | $62.56M | -61.8% |
| 2020 | $163.58M | +1348.4% |
| 2019 | $11.29M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $257.62M | +1717.5% |
| 2024 | $14.18M | -34.0% |
| 2023 | $21.46M | -34.5% |
| 2022 | $32.79M | -47.6% |
| 2021 | $62.56M | -61.8% |
| 2020 | $163.58M | +1348.4% |
| 2019 | $11.29M | — |